Eli Lilly & Company declined the applications on both the occasion, citing the reason that it is really challenging for them to sign volunt...

Under the alliance, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary li...

MSN Labs had earlier launched a Covid treatment portfolio of Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Osel...

Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laborator...

Experts are of the view that the clinicians can use it in their wisdom, but decided against recommending the drug in the national guideline...

The company has issued additional royalty-free, non-exclusive voluntary licences to Dr Reddy's, MSN Laboratories and Torrent Pharmaceutical...

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg and Oselow ...

The Hyderabad-based firm said it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company fo...

As the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements th...

Baricitinib has been given restricted emergency use approval by India's drug regulator for use in combination with remdesivir for the treat...

In its application, Natco has cited the unmet medical needs due to the lack of supply and affordability in light of the grave and life-thre...

Making its case, Natco’s application said Olumiant is not manufactured in India — less than 9,000 tablets were imported in 2019 and 2020, a...

In a statement, the Hyderabad headquartered pharma company said Baricitinib in combination with Remdesivir is used for the treatment of Cov...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...

Natco had in December sought a waiver of the clinical trial requirement for the emergency use of baricitinib tablets in Covid-19 treatment,...

Natco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...

The Subject Expert Committee (SEC) that advises the drug regulatory authority on new drugs, vaccines for Covid gave its permission to the c...